May 26, 2026 | Blog
Strategic relevance in global clinical research is not granted. It is earned. Every sponsor has a line in its portfolio strategy. Above that line sit the countries and sites trusted with pivotal trials, adaptive designs, first-in-human studies and complex oncology...
May 15, 2026 | Blog
By now, the argument for Africa’s inclusion in global clinical research is well established. The scientific rationale is clear. The public health need is clear. The access imperative is clear. But sponsors do not place complex Phase II and III trials solely on the...
May 7, 2026 | Blog
What if many clinical trial delays attributed to African sites begin much earlier — in weak feasibility design? When a study misses its first-patient-in date or enrolment lags, the explanation is often reduced to a familiar shorthand: “Africa is difficult.” But that...
May 4, 2026 | Blog
African trial start-up is often described as slow. It is one of the most durable assumptions in global clinical development, and one of the least examined. It appears in sponsor discussions, conference panels, and country-selection assumptions. But clinical trial...
Apr 25, 2026 | Blog
Malaria remains one of the most serious public health threats across Africa. According to the World Health Organization (WHO), there were an estimated 282 million malaria cases globally in 2024 and 610,000 malaria deaths. The WHO African Region accounted for 95% of...
Apr 23, 2026 | Blog
Africa carries a substantial share of the global disease burden but continues to host only a small proportion of global clinical trials (1). This imbalance affects where evidence is generated, whose populations are represented, and how confidently findings can be...
